<?xml version="1.0" encoding="UTF-8"?>
<Pathway xmlns="http://pathvisio.org/GPML/2013a" Name="Defective Intrinsic Pathway for Apoptosis" Organism="Homo sapiens">
  <Comment Source="WikiPathways-description">Defects in the regulation of the intrinsic pathway for apoptosis are involved in diseases associated with increased cell loss, such as neurodegenerative diseases, as well as in diseases associated with impaired elimination of harmful cells, such as cancer and autoimmunity. For review, please refer to Reed 2001, Lavrik et al. 2009, and Tuzlak et al. 2016.&lt;br&gt;&lt;br&gt;So far, Reactome has annotated apoptosis defects associated with the loss of function of the CDKN2A gene product p14ARF in cancer, loss of function of TP53 in cancer, and CDK5 dysregulation in neurodegenerative diseases. 
 View original pathway at [http://www.reactome.org/PathwayBrowser/#DIAGRAM=9734009 Reactome].</Comment>
  <Comment Source="Reactome-Converter">Pathway is converted from Reactome ID: 9734009</Comment>
  <Comment Source="Reactome-version">Reactome version: 88</Comment>
  <Comment Source="Reactome Author">Reactome Author: Orlic-Milacic, Marija</Comment>
  <BiopaxRef>ec2</BiopaxRef>
  <BiopaxRef>d4d</BiopaxRef>
  <BiopaxRef>ccb</BiopaxRef>
  <Attribute Key="reactome_id" Value="9734009" />
  <Graphics BoardWidth="353.0" BoardHeight="287.0" />
  <DataNode TextLabel="Neurodegenerative&#xA;Diseases" GraphId="a58f3" Type="Pathway">
    <Comment Source="Reactome">Neurodegenerative diseases manifest as the progressive dysfunction and loss of neurons, which is frequently accompanied by formation of misfolded protein deposits in the brain. Classification of neurodegenerative diseases is based on clinical symptoms, which depend on the anatomical region affected by neuronal dysfunction, the identity of misfolded proteins and cellular and subcellular pathology.&lt;br&gt;In Alzheimerâ€™s disease (AD), beta-amyloid protein (APP) deposits form in the extracellular space, where they can make plaques, while abnormally phosphorylated tau protein (MAPT) accumulates in neuronal cells.&lt;br&gt;Beside AD, neuronal and/or glial inclusions of hyperphosphorylated tau are also found in Pick disease (PiD), neurofibrillary tangle-dementia (NFT), primary age-related tauopathy (PART), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), argyrophilic grain disease (AGD) and globular glial tauopathies (GGT).&lt;br&gt;In prion disease, such as Creutzfeldt-Jakob disease, deposits of PrP protein are formed mostly in the extracellular and presynaptic space. PrP deposits in neuronal cell bodies are mainly confined to endosomes and lysosomes, which is attributed to neuronal uptake of pathological proteins and intercellular prion spreading.&lt;br&gt;In Parkinson disease (PD) and dementia with Lewy bodies (DLB), deposits of alpha-synuclein (SNCA) are formed in the cytoplasm of neuronal cell bodies and neurites. In multiple system atrophy (MSA), deposits of alpha-synuclein form in the cytoplasm of glial cells (Papp-Lantos bodies).&lt;br&gt;Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) are characterized by ubiquitin-positive cytoplasmic inclusions of TAR DNA-binding protein 43 (TARDBP, commonly known as TDP-43), a protein that normally localizes to the nucleus. Pathological TDP-43 inclusions have been associated with the TDP-43 gene mutations, as well as mutations in several other genes, including C9orf72, GRN, VCP, SQSTM1, DCTN1 and OPTN. TDP-43 inclusions have also been reported in AD, DLB, hippocampal sclerosis (HS) and chronic traumatic encephalopathy.&lt;br&gt;FUS protein-positive inclusion bodies are found in familial ALS, caused by mutations in the FUS gene, as well as in a small subgroup of FTLD-related diseases. FUS-positive inclusions may be accompanied by FET protein-positive inclusions.&lt;br&gt;For a detailed review of molecular pathology of neurodegenerative diseases, please refer to Kovacs 2016.&lt;br&gt;Within this broad domain, the process by which APP-triggered deregulation of CDK5 (cyclin-dependent kinase 5) triggers multiple neurodegenerative pathways associated with Alzheimer's disease has been annotated.</Comment>
    <BiopaxRef>e0a</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="192.5" CenterY="224.0" Width="255.0" Height="66.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-8863678" />
  </DataNode>
  <DataNode TextLabel="Defective Intrinsic&#xA;Pathway for&#xA;Apoptosis Due to&#xA;p14ARF Loss of&#xA;Function" GraphId="dbb73" Type="Pathway">
    <Comment Source="Reactome">Cancer-derived missense mutations in the CDKN2A gene that affect the C-terminal arginine-rich region of p14ARF (also known as CDKN2A transcription isoform 4, CDKN2A-4, p14 or ARF) impair p14ARF binding to the mitochondrial matrix protein C1QBP and interfere with p53-mediated apoptosis. Many mutations in the CDKN2A locus that affect C-terminal arginines of p14ARF are silent in p16INK4A (CDKN2A-1) (Itahana and Zhang 2008).</Comment>
    <BiopaxRef>cc3</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="192.5" CenterY="138.0" Width="255.0" Height="78.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-9645722" />
  </DataNode>
  <DataNode TextLabel="Loss of Function of&#xA;TP53 in Cancer" GraphId="e2d5f" Type="Pathway">
    <Comment Source="Reactome">TP53 is the most frequently mutated tumor suppressor gene, with mutations present in more than 50% of human tumors and germline mutation in TP53 being underlying cause of the cancer-predisposing Li-Fraumeni syndrome (reviewed in Monti et al. 2020). The TP53 gene maps to chromosomal band 17p13 and encodes a transcription factor that contains four functional domains. A transactivation domain (TAD) involves amino acid residues 1-61 and is involved in interaction with components of the transcription machinery. A DNA binding domain (DBD) involves amino acid residues 94-290 and interacts with specific DNA target sequences called p53 response elements. A C-terminal domain (CTD) involves residues 357-393 and regulates DNA binding (reviewed in Monti et al. 2020). A tetramerization domain (TD) involves amino acids 325-355 and is needed for the formation of TP53 homotetramers. TP53 is considered the â€œguardian of the genomeâ€� (Lane 1992) as it is activated by DNA damage to initiate, depending on the amount of damage, cell cycle arrest, senescence or apoptosis (reviewed in Reinhardt and Schumacher 2012). In addition, TP53 regulates the expression of DNA repair genes, and is involved in the regulation of metabolism and autophagy (reviewed in Monti et al. 2020).&lt;br&gt;Most cancer-derived TP53 mutations are missense mutations that affect the central DNA binding domain of TP53 (amino acid residues 94-312). Eight hotspot amino acid substitutions in this region (R175H, G245S, R248Q, R248W, R249S, R273H, R273S and R282W) are found in close to 30% of TP53-mutated cancers. Based on their functional impact, TP53 mutations can be classified as 1) loss-of-function (LOF), 2) partial LOF (which may involve temperature sensitivity); 3) wild type-like (WT-L) or super-transactivating (ST) mutants; 4) mutants with altered specificity (AS), which are active or partially active on some but inactive on other TP53 target genes; 5) dominant-negative (DN) mutants, able to tetramerize with and inhibit the activity of the wild type TP53 protein. Some of the TP53 mutants, especially in the category of ST and AS mutants, are gain-of-function (GOF) mutants, able to interact with novel target genes and/or novel components of the transcriptional machinery (reviewed in Monti et al. 2020, and Gencel-Augusto and Lozano 2020).&lt;br&gt;Due to the complex function of WT-L, ST, AS and DN mutants of TP53, we have so far focused on annotating LOF mutants of TP53 which are unable to oligomerize due to mutations in the TD. Although accounting for a small percent of TP53 mutants, TD mutant are therefore considered to be completely defective in transcriptional activity, with no possibility of AS, DN and GOF effects (ChÃ¨ne and Bechter 1999, reviewed in ChÃ¨ne 2001, and Kamada et al. 2016). However, when overexpressed, some missense TD mutants of TP53 can form homotetramers and heterotetramers with the wild type TP53 which are partially functional and some extent of AS, DN and GOF effects may not be excluded for those mutants (Atz et al. 2000, reviewed in ChÃ¨ne 2001). In addition, the synthetic mutant p153(1-320) which consists of the first 320 amino acids and lacks the TD and CTD, while unable to tetramerize, can form stacked oligomers at the recombinant target gene promoter and induce transcription at a low level. Stacked oligomers are formed through interactions that involve amino acid residues outside the TD, which are facilitated by the presence of a target DNA sequence (Stenger et al. 1994).</Comment>
    <BiopaxRef>a46</BiopaxRef>
    <BiopaxRef>a15</BiopaxRef>
    <BiopaxRef>b2b</BiopaxRef>
    <BiopaxRef>f91</BiopaxRef>
    <BiopaxRef>b3d</BiopaxRef>
    <BiopaxRef>dd1</BiopaxRef>
    <BiopaxRef>a54</BiopaxRef>
    <BiopaxRef>c8e</BiopaxRef>
    <BiopaxRef>a6e</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="194.5" CenterY="66.0" Width="257.0" Height="46.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-9723907" />
  </DataNode>
  <InfoBox CenterX="0.0" CenterY="0.0" />
  <Biopax>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="ec2">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">11425640</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Apoptosis-regulating proteins as targets for drug discovery.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Reed JC.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="d4d">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">19756299</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Understanding apoptosis by systems biology approaches.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Lavrik IN, Eils R, Fricker N, Pforr C, Krammer PH.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="ccb">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">27798841</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interrogating the relevance of mitochondrial apoptosis for vertebrate development and postnatal tissue homeostasis.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Tuzlak S, Kaufmann T, Villunger A.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="e0a">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">26848654</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Molecular Pathological Classification of Neurodegenerative Diseases: Turning towards Precision Medicine.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Kovacs GG.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="cc3">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">18538737</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Mitochondrial p32 is a critical mediator of ARF-induced apoptosis.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Itahana K, Zhang Y.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="a46">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">22265392</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">The p53 network: cellular and systemic DNA damage responses in aging and cancer.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Reinhardt HC, Schumacher B.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="a15">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">33194757</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Heterogeneity of &lt;i&gt;TP53&lt;/i&gt; Mutations and P53 Protein Residual Function in Cancer: Does It Matter?</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Monti P, Menichini P, Speciale A, Cutrona G, Fais F, Taiana E, Neri A, Bomben R, Gentile M, Gattei V, Ferrarini M, Morabito F, Fronza G.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="b2b">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">1614522</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Cancer. p53, guardian of the genome.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Lane DP.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="f91">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">10064694</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">p53 mutants without a functional tetramerisation domain are not oncogenic.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Chène P, Bechter E.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="b3d">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">11420672</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">The role of tetramerization in p53 function.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Chène P.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="dd1">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">10653977</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Function, oligomerization, and conformation of tumor-associated p53 proteins with mutated C-terminus.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Atz J, Wagner P, Roemer K.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="a54">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">7813439</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">p53 oligomerization and DNA looping are linked with transcriptional activation.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Stenger JE, Tegtmeyer P, Mayr GA, Reed M, Wang Y, Wang P, Hough PV, Mastrangelo IA.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="c8e">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">32873579</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">p53 tetramerization: at the center of the dominant-negative effect of mutant p53.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Gencel-Augusto J, Lozano G.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="a6e">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">26572807</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Tetramer formation of tumor suppressor protein p53: Structure, function, and applications.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Kamada R, Toguchi Y, Nomura T, Imagawa T, Sakaguchi K.</bp:AUTHORS>
    </bp:PublicationXref>
  </Biopax>
</Pathway>

